info@afternoonnews.in +91 98940 - 95096

Today Date : Friday, May 24, 2024

PHESGO fixed-dose combination injection for breast cancer treatment introduced in India

PHESGO fixed-dose combination injection for breast cancer treatment introduced in India

Roche Pharma has announced the India launch of PHESGO – a fixed-dose formulation in oncology to combine two monoclonal antibodies - Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase (PH-Perjeta + Herceptin; ES-Easy; GO- Go).Administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer, it is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.

According to official communication from the company, it is administered as a single injection just under the skin in the thigh. Takes a few minutes compared to hours with IV formulations for each round of treatment, thus reducing chair time for patients by 90%. Provides a faster, more convenient, and less invasive means to receive breast cancer therapy.

 Faster administration through PHESGO gives the confidence and frees up time for everyone (patients, caregivers, doctors, and paramedical staff)  and it frees up bed capacity faster and provides cost saving benefits to healthcare systems.